WP
CGON icon

Woodline Partners’s CG Oncology CGON Stock Holding History

Woodline Partners’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.4M Buy
492,891
+391
+0.1% +$22.2K 0.13% 215
2025
Q4 		$20.4M Sell
492,500
-78,978
-14% -$3.27M 0.08% 307
2025
Q3 		$23M Sell
571,478
-57,879
-9% -$1.68M 0.11% 252
2025
Q2 		$16.4M Sell
629,357
-135,000
-18% -$3.25M 0.09% 326
2025
Q1 		$18.7M Buy
764,357
+135,472
+22% +$3.81M 0.12% 240
2024
Q4 		$18M Buy
628,885
+22,987
+4% +$786K 0.12% 229
2024
Q3 		$22.9M Buy
605,898
+80,699
+15% +$2.83M 0.19% 174
2024
Q2 		$16.6M Hold
525,199
– – 0.16% 193
2024
Q1 		$23.1M Buy
+525,199
New +$21.4M 0.21% 147

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners's CGON Position: Q1 2026 in Review

Woodline Partners increased its CG Oncology (CGON) stake by 0.08% in Q1 2026, buying an estimated $22.2K and bringing the position to 492,891 shares worth $33.4M. The position accounts for 0.13% of the portfolio, ranked #215.

Woodline Partners first reported a position in CGON in Q1 2024 and has held it in 9 quarters since. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Woodline Partners held 492,891 shares of CG Oncology worth $33.4M as of Q1 2026.
  • Woodline Partners bought 391 CG Oncology shares in Q1 2026, an estimated $22.2K.
  • CG Oncology made up 0.13% of Woodline Partners's portfolio in Q1 2026, its #215 holding.
  • Woodline Partners first reported a position in CG Oncology in Q1 2024 and has held it in 9 quarters since.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.